Cheema Abdullah A, Cheema Haider R
Ophthalmology, Royal Glamorgan Hospital, Cardiff, GBR.
Ophthalmology, Royal Berkshire Hospital, Reading, GBR.
Cureus. 2024 Jan 12;16(1):e52183. doi: 10.7759/cureus.52183. eCollection 2024 Jan.
This review examines the evolution, current status, and future potential of minimally invasive glaucoma surgeries (MIGS), a significant advancement in the treatment of glaucoma, a leading cause of irreversible blindness. MIGS offer a less invasive alternative to traditional glaucoma surgeries, primarily aimed at reducing intraocular pressure, minimizing tissue trauma, and providing a safer profile. With the emergence of devices such as the Trabectome, iStent, and others, MIGS have expanded the surgical toolkit, allowing personalized, patient-centered care. Despite their advantages, MIGS face challenges such as efficacy in severe cases, long-term data, and accessibility. Ongoing research and technological innovations continue to refine their capabilities and applications, promising to further transform glaucoma management and patient outcomes. This paper provides an in-depth analysis of MIGS, reflecting on their impact and contemplating future directions in this dynamically evolving field.
本综述探讨了微创青光眼手术(MIGS)的发展历程、现状及未来潜力。青光眼是不可逆失明的主要原因,而MIGS是青光眼治疗领域的一项重大进展。MIGS为传统青光眼手术提供了侵入性较小的替代方案,主要目的是降低眼压、减少组织创伤并提供更安全的手术方式。随着Trabectome、iStent等设备的出现,MIGS扩展了手术工具库,实现了个性化的、以患者为中心的治疗。尽管MIGS具有诸多优势,但仍面临一些挑战,如在严重病例中的疗效、长期数据以及可及性等问题。正在进行的研究和技术创新不断提升其性能和应用范围,有望进一步改变青光眼的治疗方式并改善患者预后。本文对MIGS进行了深入分析,反思了其影响,并展望了这一动态发展领域的未来方向。